|
12 Nov 2007 |
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
|
|
12 Nov 2007 |
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra® (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
|
|
12 Nov 2007 |
Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
|
|
11 Nov 2007 |
AtheroGenics Modifies ANDES Clinical Trial Discontinuing Highest Dose of AGI-1067
|
|
09 Nov 2007 |
CRESTOR(R) Now Indicated To Slow The Progression Of Atherosclerosis In Patients With Elevated Cholesterol
|
|
09 Nov 2007 |
VIVUS Initiates Pivotal Phase 3 Trial in Obese Patients and Announces Qnexa Dose
|
|
09 Nov 2007 |
Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease
|
|
09 Nov 2007 |
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
|
|
09 Nov 2007 |
Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
|
|
09 Nov 2007 |
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
|
|
08 Nov 2007 |
KeyNeurotek Pharmaceuticals Initiates Phase I Study With Cannabinoid Receptor-Agonist
|
|
08 Nov 2007 |
Dynogen’s prokinetic drug, DDP733, enters Phase 2b for irritable bowel syndrome with constipation
|
|
08 Nov 2007 |
CV Therapeutics' Selective Adenosine A1 Agonist Tecadenoson Shows Synergistic Effect with Ultra Low Dose Beta Blocker in Preclinical Atrial Fibrillation Model
|
|
08 Nov 2007 |
Merck Submits European Marketing Authorization Application for Sapropterin as a Treatment for Hyperphenylalaninemia
|
|
08 Nov 2007 |
Shire expands its Human Genetic Therapies pipeline through in-licensing agreement with Amicus Therapeutics
|
|
08 Nov 2007 |
Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
|
|
08 Nov 2007 |
Synta Pharmaceuticals Initiates Phase 1 Clinical Trial of STA-9090, a Novel Hsp90 Inhibitor
|
|
08 Nov 2007 |
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
|
|
08 Nov 2007 |
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
|
|
07 Nov 2007 |
Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis
|
|
07 Nov 2007 |
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
|
|
07 Nov 2007 |
Neuren reports successful NNZ-2566 Phase 1b safety trial results
|
|
07 Nov 2007 |
Rifalazil trial (PROVIDENCE-1) fails to provide significant clinical benefit in patients with peripheral arterial disease
|
|
07 Nov 2007 |
Biovail Enters into Development Agreement
|
|
07 Nov 2007 |
Biovail Enters into Development Agreement
|
